GILD - Gilead Sciences Inc. (GILD) BofA Securities 2024 Health Care Conference (Transcript)
2024-05-14 16:25:24 ET
Gilead Sciences, Inc. (GILD)
BofA Securities 2024 Health Care Conference
May 14, 2024, 02:20 PM ET
Company Participants
Geoff Meacham - Bank of America Securities
Conference Call Participants
Andrew Dickinson - Chief Financial Officer
Presentation
Geoff Meacham
For the first day of the BofA Healthcare Conference. My name is Geoff Meacham. I'm the senior biopharma analyst here. We're thrilled today to have Gilead Sciences. And with me on stage is CFO, Andy Dickinson. Andy, good to see you.
Andrew Dickinson
Thank you. Thank you for having us again. We're thrilled to be here.
Geoff Meacham
So we won't do any prepared remarks coming out of the quarter, maybe just let's get right into the core HIV business. So BIKTARVY has done super, super well. You do have some competitive dynamics playing out, but that's not unusual for you guys. Give us kind of the look forward about the health of the – just in the treatment setting, the HIV business driven by BIKTARVY, then we'll get into land and the development.
Andrew Dickinson
Sure. Yeah, be happy to. We had a very strong first quarter. And the business has done great over for decades now, including last couple of years.
In the first quarter, you saw BIKTARVY on a year-over-year basis take another 3 percentage points in terms of the overall HIV treatment market. It grew in terms of sales 10% year-over-year. BIKTARVY is used in I think 49% of HIV patients in the United States. Most of those get BIKTARVY out of the gate as their first HIV treatment. And they tend to stay on for a very long time because it is the gold standard. And I'll talk a little bit about why it's such a special combination product....
Gilead Sciences, Inc. (GILD) BofA Securities 2024 Health Care Conference (Transcript)